Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

We evaluated early disease progression and its impact on overall survival (OS) in previously untreated follicular lymphoma patients in GALLIUM (clinicaltrials.gov identifier: 01332968), and investigated the effect on early disease progression of the two randomization arms: obinutuzumab-based versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Seymour, John F., Marcus, Robert, Davies, Andrew, Gallop-Evans, Eve, Grigg, Andrew, Haynes, Andrew, Herold, Michael, Illmer, Thomas, Nilsson-Ehle, Herman, Sökler, Martin, Dünzinger, Ulrich, Nielsen, Tina, Launonen, Aino, Hiddemann, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545851/
https://www.ncbi.nlm.nih.gov/pubmed/30573503
http://dx.doi.org/10.3324/haematol.2018.209015

Ejemplares similares

Ejemplares similares